Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Izidore Lossos, MD
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06796998CT.gov Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | — | Recruiting | — | — | — |
NCT06563596CT.gov Epco, Zanu, Ritux for R/R FL or MZL | — | Recruiting | — | — | — |
NCT04542824CT.gov Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | — | Active Not Recruiting | — | — | — |
NCT04358458CT.gov First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | — | Terminated | — | — | — |
NCT03625037CT.gov First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marginal Zone Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epcoritamab (this asset) | Izidore Lossos, MD | P2 | CCC · 55 |
| Etoposide | University of Miami | P2 | BBB |
| Orelabrutinib | Henan Cancer Hospital | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Nivestim | Fred Hutchinson Cancer Center | P2 | BBB |
| Vincristine Sulfate | Mayo Clinic | P2 | BBB |
| Fludarabine | Paolo Caimi, MD | P2 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Marginal Zone Lymphoma cohort
Other indications for Epcoritamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P2 | BB · 65 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 65 |
| Primary Central Nervous System Lymphoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epcoritamab in Marginal Zone Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/epcoritamab-marginal-zone-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →